AstraZeneca licenses novel agent for the treatment of cardiometabolic conditions and obesity
Global rights to Eccogene’s next-generation oral glucagon-like peptide 1 receptor agonist, ECC5004 as monotherapy and combination therapies.AstraZeneca and Eccogene have entered into an exclusive licence agreement for ECC5004, an investigational oral once-daily glucagon-like peptide 1 receptor agonist (GLP-1RA) for the treatment of obesity, type-2 diabetes and other cardiometabolic conditions. Preliminary results from the Phase I trial have shown a differentiating clinical profile for ECC5004, with good tolerability and encouraging glucose and body weight reduction across the dose levels